GlobeNewswire·Sep 15, 2026, 8:00 AM ET

Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development

Allarity Therapeutics announced the Japan Patent Office granted Japanese Patent No. 7917283 for its stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic.
The newly granted patent provides intellectual property protection in Japan extending into 2039.
The patent covers methods for predicting clinical benefit from stenoparib using gene-expression profiles from tumor samples & selecting patients most likely to benefit via the DRP® test.
Allarity previously secured U.S. patent protection for the DRP® extending into April 2042, along with coverage in select European jurisdictions & Australia, while maintaining pending applications in other international markets.
Stenoparib is a dual-targeted PARP & tankyrase inhibitor originally developed by Eisai, with Allarity holding exclusive global rights to its development & commercialization.
The company completed a Phase 2 trial for advanced ovarian cancer showing promising clinical benefit, with an amended protocol now enrolling platinum-resistant or platinum-ineligible patients since summer 2025.
A separate Phase 2 trial evaluating stenoparib combined with temozolomide for relapsed small cell lung cancer began enrolling in early 2026 at U.S. Department of Veterans Affairs sites.
The DRP® platform uses messenger RNA expression profiles from biopsies to generate predictive scores, having demonstrated statistically significant outcome predictions across dozens of studies.